The burden of rare cancers among adults in the Canton of Geneva, Switzerland, from 2011 to 2020
These findings highlight the critical challenges and requirements of targeted research and improving care strategies for rare cancers. Efforts combatting such cancers include European Reference Networks and the Swiss Sarcoma Network, which have improved access to care via collaborative efforts. In Switzerland, Molecular Tumor Boards have leveraged genomic knowledge to refine treatments and allow patient participation in clinical trials. Early referral to such boards for aggressive or treatment-limited cancers can streamline care and facilitate patient access to specialist centers. However, Switzerland requires more comprehensive data on the distribution of rare cancers in terms of age, gender, and region to improve management strategies at national levels.
Authors
- E. Fournier (ORCID: https://orcid.org/0000-0001-6717-8020)
- Laura Botta (ORCID: https://orcid.org/0000-0002-2793-5338)
- Alice Bernasconi (ORCID: https://orcid.org/0000-0001-8522-6882)
- Elisabetta Rapiti (ORCID: https://orcid.org/0000-0002-7847-7728)
- Nathalie Le Bot (ORCID: https://orcid.org/0000-0002-9486-5050)
- Marie-Laure Amram
Institutions
- University of Geneva (CH)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.3389/fonc.2025.1557424
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00